Scientists Successfully Apply Gene Therapy against Retinitis Pigmentosa

A collaboration between scientists in the UK and the USA has shown that gene therapy can give life-long protection to the light-sensitive photoreceptor cells responsible for colour vision in a mouse model of the most common inherited eye disorder.

  These findings are significant because they open up a new line of research to prevent nerve…

Retinal function, structure changes in proliferative diabetic retinopathy revealed

Patients with proliferative diabetic retinopathy (PDR) exhibit marked visual dysfunction and structural changes in both the inner and outer retinal layers, research findings indicate. Retinal function was evaluated using a number of tests, including contrast sensitivity, frequency doubling perimetry (FDP) and photostress testing. And semiautomatically segmented spectral-domain optical coherence tomography scans were used to quantify…

New drug candidate is promising therapeutic option for angiogenic retinal diseases

A research team led by scientists at Beth Israel Deaconess Medical Center (BIDMC) and the University of New Mexico School of Medicine has identified a small molecule that treats animal models of aged macular degeneration (AMD) and retinopathy of prematurity (ROP) by preventing the overgrowth of blood vessels that are characteristic of these two retinal…

Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model

Gene therapy preserved vision in a study involving dogs with naturally occurring, late-stage retinitis pigmentosa, according to research funded by the National Eye Institute (NEI), part of the National Institutes of Health. The findings contribute to the groundwork needed to move gene therapy forward into clinical trials for people with the blinding eye disorder, for…

Aerie Pharmaceuticals Reports Positive Rhopressa™ Phase 3 Efficacy Results

Aerie Pharmaceuticals, a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today reported the successful results of its second Phase 3 trial for Rhopressa™, a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Read the entire…

Scientists find a way to ‘shrink’ blind spot in human eye

The optic nerve that sends visual signals to the brain must pass through the retina which creates a hole in that light-sensitive layer of tissue. When images project to that precise location, we miss them. This blind spot can be ‘shrunk’ despite the fact that the hole in our visual field cannot be. The findings…

Proteomic Studies of Age-Related Ocular Diseases

A Cleveland Clinic lab has found evidence to support the theory that age-related macular degeneration (AMD) is an inflammatory disease with varying ways to progress to advanced dry and wet AMD.  Focusing on proteomic studies to discover biomarkers and molecular mechanisms of AMD and glaucoma, John W. Crabb, PhD, and his colleagues found many proteins…

Preserving photoreceptor cells following retinal injury: Inhibition of alternate complement pathway revealed

Retinal detachment can occur as a result of either blunt trauma or as a side effect of a variety of ophthalmic diseases, including diabetic retinopathy, ocular tumors, and age-related macular degeneration.  There is a significant increase in the immune system’s ‘alternative complement pathway’ following retinal detachment, researchers report, adding that this pathway facilitated early photoreceptor…